HALOG (Page 2 of 2)

ADVERSE REACTIONS

The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings (reactions are listed in an approximate decreasing order of occurrence): burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.

OVERDOSAGE

Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS: General).

DOSAGE AND ADMINISTRATION

Apply HALOG SOLUTION (Halcinonide Topical Solution, USP) 0.1% to the affected area two to three times daily.

Occlusive Dressing Technique

Occlusive dressings may be used for the management of psoriasis or other recalcitrant conditions. Apply the solution to the lesion, cover with a pliable nonporous film, and seal the edges. If needed, additional moisture may be provided by covering the lesion with a dampened clean cotton cloth before the nonporous film is applied or by briefly wetting the affected area with water immediately prior to applying the medication. The frequency of changing dressings is best determined on an individual basis. It may be convenient to apply HALOG SOLUTION under an occlusive dressing in the evening and to remove the dressing in the morning (i.e., 12-hour occlusion). When utilizing the 12-hour occlusion regimen, additional solution should be applied, without occlusion, during the day. Reapplication is essential at each dressing change.

If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

HOW SUPPLIED

HALOG® SOLUTION (Halcinonide Topical Solution, USP) 0.1% is supplied in plastic squeeze bottles containing, 60 mL (NDC 10631-095-20), and 120 mL (NDC 10631-095-10) of solution.

Storage

Store at room temperature; avoid freezing and temperatures above 104° F.

To report SUSPECTED ADVERSE REACTIONS, contact Sun Pharmaceutical Industries, Inc. at 1-800-406-7984 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Distributed by:

Sun Pharmaceutical Industries, Inc.

Cranbury, NJ 08512

Revised July 2019

PPK-8860-0

29

LABEL PRINCIPAL DISPLAY PANEL-60mL

PDP-60mL
(click image for full-size original)

LABEL PRINCIPAL DISPLAY PANEL-120mL

PDP-120mL
(click image for full-size original)

LABEL PRINCIPAL DISPLAY PANEL-Physician Sample

PDP-PS
(click image for full-size original)
HALOG
halcinonide topical solution
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:10631-095
Route of Administration TOPICAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
HALCINONIDE (HALCINONIDE) HALCINONIDE 1 mg in 1 mL
Inactive Ingredients
Ingredient Name Strength
EDETATE DISODIUM
POLYETHYLENE GLYCOL 300
WATER
BUTYLATED HYDROXYTOLUENE
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:10631-095-20 1 BOTTLE, PLASTIC in 1 CARTON contains a BOTTLE, PLASTIC
1 60 mL in 1 BOTTLE, PLASTIC This package is contained within the CARTON (10631-095-20)
2 NDC:10631-095-10 1 BOTTLE, PLASTIC in 1 CARTON contains a BOTTLE, PLASTIC
2 120 mL in 1 BOTTLE, PLASTIC This package is contained within the CARTON (10631-095-10)
3 NDC:10631-095-98 4 BOTTLE, PLASTIC in 1 CARTON contains a BOTTLE, PLASTIC (10631-095-06)
3 NDC:10631-095-06 5 mL in 1 BOTTLE, PLASTIC This package is contained within the CARTON (10631-095-98)
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA017823 03/18/2020
Labeler — Sun Pharmaceutical Industries, Inc. (146974886)
Establishment
Name Address ID/FEI Operations
Taro Pharmaceuticals Inc. 206263295 MANUFACTURE (10631-095)

Revised: 05/2021 Sun Pharmaceutical Industries, Inc.

Page 2 of 2 1 2

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2021. All Rights Reserved.